Form 4: Organon SVP Lynette Holzbaur Equity Transaction Update
Statement of Changes in Beneficial Ownership
SVP and Corporate Controller Lynette Holzbaur reported the vesting of restricted stock units and the receipt of new equity grants at Organon & Co.
Summary
- Lynette Holzbaur, SVP and Corporate Controller, exercised and vested 10,967 restricted stock units (RSUs) on March 31, 2026.
- A total of 3,126 shares were withheld by the company to cover tax obligations at a price of $5.70 per share.
- The reporting person received new grants of 75,125 and 41,736 RSUs, totaling 116,861 new units.
- Following these transactions, the reporting person holds 26,402.427 shares of common stock directly.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral administrative filing regarding executive compensation, which does not signal a change in company fundamentals.
Positives
- The reporting person maintains a significant equity stake in the company, aligning interests with shareholders.
- The issuance of new RSUs serves as a long-term retention incentive for a key member of the financial leadership team.
Negatives
- The transaction involved the withholding of shares for tax purposes, which is standard but reduces the net share increase for the executive.
Risks
- Future value of equity grants is subject to market volatility and the company's stock performance.
Future Outlook
The newly granted RSUs are scheduled to vest in three equal annual installments on March 31, 2027, 2028, and 2029, contingent upon continued service.
Industry Context
StockSavvy.ai notes that equity compensation filings for senior financial officers are standard corporate practice and generally reflect routine compensation cycles rather than shifts in strategic outlook.
Comparison to Industry Standards
- The use of three-year graded vesting schedules for RSU grants is consistent with standard executive compensation practices in the pharmaceutical and life sciences sectors.
- Tax withholding via share cancellation is a standard administrative procedure for equity-based compensation.
Stakeholder Impact
- Shareholders should view this as routine compensation activity with no immediate impact on company operations or financial position.
Next Steps
- Vesting of the first installment of the new RSU grants on March 31, 2027.
Key Dates
| Date | Description |
|---|---|
| 03/31/2023 | Original grant date of 12,755 RSUs. |
| 03/31/2025 | Original grant date of 20,147 RSUs. |
| 03/30/2026 | Market closing price date used for tax withholding calculation. |
| 03/31/2026 | Transaction date for RSU vesting and new grants. |
| 04/02/2026 | Filing date of the Form 4. |
| 03/31/2027 | First installment vesting date for new RSU grants. |
| 03/31/2028 | Second installment vesting date for new RSU grants. |
| 03/31/2029 | Final installment vesting date for new RSU grants. |
Keywords
Organon, OGN, Form 4, Insider Trading, Equity Compensation, Restricted Stock Units, Corporate Governance
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.